FDA-filed SPL labeling · retrieved through openFDA

Mycophenolic Acid

Mycophenolic acid is an immunosuppressant used to help prevent organ rejection in kidney transplant patients.

Brand name Myfortic
Drug class ⓘ Antimetabolite Immunosuppressant
Rx Form 1 Route Oral
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 21 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveJul 29, 2026
Clinical labels in scope ⓘ21
AvailabilityRx
Earliest approval/marketing year ⓘ2001
FDA-listed product records ⓘ121
Boxed warningYes
How we combine label and product data →
✓No current FDA shortage listed · checked Sep 23, 2026 🚨Recall on record
⭐ Mycophenolic Acid at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Mycophenolic acid delayed-release tablets are a key part of the medication regimen used to prevent kidney rejection after transplant, always used alongside cyclosporine and corticosteroids. Because they suppress your immune system, they require close monitoring for infections, blood cell changes, and long-term cancer risk. Following your prescribed schedule, keeping all lab appointments, and using effective birth control are essential parts of safe treatment.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

This medicine carries serious FDA-required warnings that every patient should know. First, using mycophenolic acid during pregnancy is linked to a very high risk of miscarriage and serious birth defects affecting the ears, face, heart, limbs, kidneys, and nervous system. Women who could become pregnant must use reliable birth control and be tested for pregnancy before and during treatment. Second, this medicine must only be prescribed by physicians experienced in transplant care, and patients must be monitored in a facility with proper lab support. Third, because it suppresses the immune system, it raises the risk of developing lymphoma and other cancers — especially skin cancer. Fourth, it significantly increases susceptibility to serious bacterial, viral, fungal, and opportunistic infections, some of which can be fatal. Report any signs of infection, unusual symptoms, or skin changes to your transplant team right away.

Read the full warning on DailyMed →

📖 Mycophenolic Acid: Patient Information Guide

A plain-language walkthrough of Mycophenolic Acid — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for▾

Mycophenolic acid delayed-release tablets are used to prevent kidney transplant rejection in both adults and certain pediatric patients.

  • Myfortic is indicated for prophylaxis (prevention) of organ rejection in adult kidney transplant patients, used in combination with cyclosporine and corticosteroids.
  • Myfortic is also indicated for pediatric kidney transplant patients aged 5 years and older who are at least 6 months past their transplant, again in combination with cyclosporine and corticosteroids.
  • Mycophenolic acid delayed-release tablets (generic) carry the same indication: prevention of organ rejection in adult kidney transplant patients, in combination with cyclosporine and corticosteroids.
  • Mycophenolic acid delayed-release tablets (generic) are also approved for pediatric kidney transplant patients aged 5 and older, at least 6 months post-transplant.
  • Neither Myfortic nor mycophenolic acid delayed-release tablets should be used interchangeably with mycophenolate mofetil (MMF) tablets or capsules without physician supervision — they are absorbed differently.
⚙️How it works▾

Mycophenolic acid blocks an enzyme called IMPDH (inosine monophosphate dehydrogenase) that immune cells — specifically T- and B-lymphocytes — absolutely need in order to multiply. By cutting off their supply of key building blocks (guanosine nucleotides), the drug puts the brakes on these cells before they can attack the transplanted kidney. Most other cells in the body have a backup pathway to make what they need, so the effect is more targeted to immune cells than to the body as a whole.

It does not become incorporated into DNA. Its primary action is stopping immune cell proliferation (overgrowth) and it has also been shown to reduce antibody production.

💊How it's taken▾

These tablets are taken by mouth twice a day, on an empty stomach — at least 1 hour before or 2 hours after a meal. Taking them with food does not change the total amount absorbed, but it delays and reduces the peak concentration, making absorption less predictable. The tablets must be swallowed whole to preserve the enteric coating that protects the stomach.

  • Dosing is individualized by your transplant team based on your body size (for children) and your response to treatment.
  • Never crush, chew, or cut the tablets.
  • Always follow your prescriber's exact instructions — do not adjust your own dose.
🤒Side effects — in detail▾

The most commonly reported side effects include:

  • Anemia (low red blood cells) and leukopenia (low white blood cells)
  • Nausea, vomiting, diarrhea, and constipation
  • Indigestion (dyspepsia)
  • Urinary tract infections
  • CMV (cytomegalovirus) infection
  • Trouble sleeping (insomnia)
  • High blood pressure
  • Tremor and headache

Seek medical help right away if you develop signs of serious infection (fever, chills, unusual fatigue), signs of severe allergic reaction (throat swelling, hives, chest pain), blood in your stool, unusual bruising or pallor, or any new neurological symptoms such as confusion or one-sided weakness. These can signal rare but life-threatening complications.

⚠️Warnings & precautions▾
  • Serious infections: This medicine lowers your immune defenses, raising the risk of bacterial, viral, fungal, and opportunistic infections — including rare but dangerous ones like BK virus kidney infection, PML (a brain infection), CMV disease, and hepatitis B or C reactivation. Some can be fatal.
  • Cancer risk: Long-term immune suppression increases the risk of lymphoma and skin cancer. Avoid excessive sun exposure and use sunscreen and protective clothing regularly.
  • Pregnancy: This medicine causes serious birth defects and a very high rate of first-trimester pregnancy loss. Effective contraception is mandatory for women of childbearing age during treatment and for 6 weeks after stopping.
  • Blood cell problems: The medicine can cause low white blood cell counts (neutropenia) or anemia, including a rare condition called pure red cell aplasia (PRCA). Regular blood tests are required, especially during the first year.
  • GI complications: Serious events including GI bleeding, intestinal perforation, and stomach ulcers have been reported. Use with caution if you have active digestive disease.
  • Acute inflammatory syndrome (AIS): A paradoxical reaction — fever, joint pain, muscle aches — can occur weeks to months after starting the medicine or after a dose increase. Tell your doctor if this happens.
  • Live vaccines: Avoid all live attenuated vaccines during treatment. Other vaccines may also be less effective.
🔀What it interacts with▾

Mycophenolic acid interacts with several common medications that can either lower its effectiveness or increase the risk of side effects:

  • Antacids (magnesium/aluminum hydroxide): Reduce absorption of mycophenolic acid — do not take at the same time.
  • Azathioprine: Both drugs block the same metabolic pathway; combining them is not recommended.
  • Cholestyramine, bile acid sequestrants, oral activated charcoal: Interfere with the drug's recycling in the body, lowering its levels — avoid concurrent use.
  • Sevelamer: May reduce mycophenolic acid levels; do not take simultaneously.
  • Cyclosporine: Can lower mycophenolic acid levels — your doctor should monitor carefully if cyclosporine is added or removed from your regimen.
  • Rifampin: Can significantly reduce mycophenolic acid levels — avoid unless your doctor determines the benefit outweighs the risk.
  • Norfloxacin + metronidazole together: May reduce mycophenolic acid levels when both antibiotics are given at the same time (but not when given individually).
  • Hormonal contraceptives: Mycophenolic acid may reduce their effectiveness — always use an additional barrier method.
  • Acyclovir, valacyclovir, ganciclovir, valganciclovir: Compete for kidney elimination with the drug's metabolite; blood counts should be monitored during coadministration.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it▾
  • Allergy: Do not take if you have had a hypersensitivity reaction to mycophenolate sodium, mycophenolic acid, or mycophenolate mofetil.
  • Pregnancy: This medicine must not be used during pregnancy unless no safer option exists — it causes birth defects and miscarriage. A pregnancy test is required before starting.
  • Women of childbearing age: Must use effective contraception during treatment and for 6 weeks after the last dose.
  • Men: Should use effective contraception with their partners during treatment and for at least 90 days after stopping; do not donate sperm during this period.
  • Blood and semen donation: Do not donate blood for at least 6 weeks after stopping; do not donate semen for at least 90 days after stopping.
  • Rare hereditary conditions: Patients with HGPRT deficiency (such as Lesch-Nyhan syndrome) should not use this medicine — it can worsen their condition.
  • Children under 5 or less than 6 months post-transplant: Safety and effectiveness have not been established in these groups.
  • Older adults: Clinical data in patients 65 and older are limited; prescribers typically exercise extra caution with dosing.
  • Breastfeeding: Data are very limited; discuss the risks and benefits with your doctor before breastfeeding while taking this medicine.
🚑If you take too much▾

Taking too much mycophenolic acid could over-suppress the immune system, raising the risk of serious infections and sepsis. Signs of overdose may include stomach pain, nausea, vomiting, diarrhea, and blood cell abnormalities such as low white blood cell or red blood cell counts. Treatment focuses on supportive care; standard dialysis is not expected to meaningfully remove the active drug due to its very high protein binding, though activated charcoal or bile sequestrants may help reduce absorption.

📡Pharmacodynamics — effects in the body▾

Mycophenolic acid selectively suppresses the proliferation (multiplication) of T- and B-lymphocytes — the immune cells responsible for attacking transplanted organs. It does this by blocking their ability to synthesize guanosine nucleotides, the building blocks they need to replicate. This cytostatic (cell-growth-stopping) effect is more targeted to lymphocytes than to most other cell types, which have an alternative pathway. It also reduces antibody production.

🔬Pharmacokinetics — how your body processes it▾

After swallowing, the enteric coating on mycophenolic acid delayed-release tablets prevents release in the acidic stomach; the drug dissolves in the neutral environment of the intestine, typically reaching peak blood levels within about 1.5 to 2.75 hours. The drug is more than 98% bound to albumin (a blood protein), and is processed mainly by the liver into an inactive metabolite (MPAG), which is cleared primarily through the urine. A second, smaller peak in drug levels occurs around 6 to 8 hours after dosing because some of the metabolite is recycled through bile and re-absorbed. The average time the drug remains active in the body (elimination half-life) ranges from 8 to 16 hours.

📦How to store it▾

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) . Protect from moisture. Dispense in a tight container (USP).

📄 Written from Mycophenolic Acid’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Mycophenolic Acid — the kind of thing our pharmacy team would talk through with you at the counter.

Why do I have to take this on an empty stomach? What happens if I take it with food? ▾
The enteric coating on the tablet is designed to release the medicine in your intestine, not your stomach. Food doesn't block absorption entirely, but it delays and lowers the peak level the medicine reaches in your blood, making it harder to keep consistent levels in your system. To keep things predictable, take it at least 1 hour before or 2 hours after eating — every time. Consistency really matters with transplant medications.
Can I ever switch to the mycophenolate mofetil (MMF) pill instead? ▾
Not on your own — and probably not without careful planning. Even though both medicines work the same way, mycophenolic acid delayed-release tablets and MMF are absorbed at different rates and are not considered interchangeable. If a switch is ever needed, your transplant doctor will oversee it closely to make sure your drug levels stay in the right range and your kidney stays protected.
I've heard this medicine raises my risk of getting sick more often. What should I watch out for? ▾
Yes, that's one of the most important things to know. Because this medicine quiets your immune system, you're more vulnerable to infections — including some serious ones that healthy people rarely get. Watch for fever, chills, unusual tiredness, skin sores, or any symptoms that seem out of the ordinary. Also tell your doctor immediately if you notice confusion, weakness on one side, or any new neurological symptoms, which can be signs of a rare but serious brain infection. Don't wait to call — early treatment for infections really matters.
I'm a woman who could get pregnant. What do I need to know? ▾
This is really important. Mycophenolic acid can cause serious birth defects and a very high rate of miscarriage — this is one of the FDA's most serious warnings for this medicine. You'll need a pregnancy test before starting and again about 8 to 10 days later. During treatment and for 6 weeks after your last dose, you must use reliable birth control. If you're using hormonal contraceptives like the pill or patch, you'll need to add a barrier method like a condom, because this medicine can reduce how well hormonal contraceptives work. Talk to your transplant team if you're thinking about pregnancy — they can help you plan safely.
Does this medicine increase my risk of cancer? ▾
It does raise the risk — mainly skin cancer and a type of cancer called lymphoma. This is because lowering your immune response, which is necessary to protect your transplanted kidney, also reduces your body's ability to catch and destroy abnormal cells. To reduce your skin cancer risk, avoid prolonged sun exposure, wear protective clothing, and use a broad-spectrum sunscreen with a high SPF every day. Make sure to mention any new or changing skin spots to your doctor.
Are there any common medicines or supplements I should avoid while taking this? ▾
Yes, a few important ones. Avoid taking antacids that contain magnesium or aluminum at the same time as your tablet — they lower how much medicine your body absorbs. Drugs like cholestyramine or activated charcoal interfere with how the medicine recycles in your body, so those should be avoided too. The antibiotic rifampin can significantly lower your mycophenolic acid levels. And if you take antiviral medicines like acyclovir or ganciclovir, your doctor will want to monitor your blood counts more closely. Always check with your transplant team before starting any new medicine, supplement, or antibiotic.
Is Mycophenolic Acid available over the counter? ▾
Mycophenolic Acid is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.
When was Mycophenolic Acid first available? ▾
Mycophenolic Acid has been available in the United States since at least 2001, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Mycophenolic Acid? ▾
Mycophenolic Acid is supplied by 30 manufacturers listed in the FDA NDC Directory, including Major Pharmaceuticals, Biocon Pharma Inc., PD-Rx Pharmaceuticals, Inc..

💬 Answers drafted from Mycophenolic Acid’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

🌿Drug & Supplement CheckerMycophenolic Acid vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Mycophenolic Acid NDCs & costs 🅰️Browse Drugs A–ZLook up any medication

💊 How Mycophenolic Acid comes

Mycophenolic Acid is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Delayed-release tablet

By mouth
Brands Myfortic
How this form is used
What it may be used for
  • Myfortic is approved to prevent organ rejection in adult kidney transplant patients, used with cyclosporine and corticosteroids
  • Myfortic is approved to prevent organ rejection in pediatric kidney transplant patients aged 5 years and older who are at least 6 months post-transplant
  • Mycophenolic acid delayed-release tablets are approved to prevent organ rejection in adult kidney transplant patients, used with cyclosporine and corticosteroids
  • Mycophenolic acid delayed-release tablets are approved for pediatric kidney transplant patients aged 5 and older who are at least 6 months post-transplant
Important instructions
  • Myfortic tablets should be taken on an empty stomach — 1 hour before or 2 hours after eating — to ensure consistent absorption
  • Myfortic tablets must be swallowed whole; do not crush, chew, or cut them, as this would damage the enteric coating
  • Mycophenolic acid delayed-release tablets should be taken on an empty stomach — 1 hour before or 2 hours after food intake
  • Mycophenolic acid delayed-release tablets must be swallowed whole; crushing, chewing, or cutting them is not permitted
Available strengths 2 strengths
180 mg 360 mg
116 FDA-listed product records ⓘ

📊 Mycophenolic Acid across the U.S. market

How Mycophenolic Acid appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1
Dose forms ⓘ
30
Manufacturers
2
Brand names
121
FDA-listed product records ⓘ
2001
First marketed ⓘ

Also listed with the FDA, not a patient dose form: Powder (5) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Major Pharmaceuticals8%
Biocon Pharma Inc.8%
PD-Rx Pharmaceuticals, Inc.7%
Novartis Pharmaceuticals Corporation7%
American Health Packaging7%
Apotex Corp7%
Other makers57%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Mycophenolic Acid is used

A general measure of how commonly Mycophenolic Acid is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Mycophenolic Acid is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

94,168
Medicaid prescriptions filled (Q1–Q4 2025)
$8.6M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Mycophenolic Acid prescribed? Of the 1,596 medications we measure, Mycophenolic Acid ranks #520 by Medicaid prescriptions — more than 67% of them.

Where Mycophenolic Acid ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #520 of 1,596
#515 Cholestyramine Resin 97,696 Rx #516 Doxylamine and Pyridox... 97,428 Rx #517 Dolutegravir 95,552 Rx #518 Cilostazol 94,961 Rx #519 Azelaic Acid Topical 94,548 Rx #520 Mycophenolic Acid 94,168 Rx #521 Amphetamine 93,374 Rx #522 Ulipristal 93,222 Rx #523 Imiquimod Topical 92,281 Rx #524 Nebivolol 91,607 Rx #525 Orphenadrine 91,158 Rx

Utilization by Mycophenolic Acid product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 360 mg delayed release oral tablet is the most-dispensed Mycophenolic Acid product — about 59% of these Medicaid prescriptions.

mycophenolic acid 360 MG Delayed Release Oral Tablet Most dispensed

55,997 Medicaid prescriptions (Q1–Q4 2025) 59% of Mycophenolic Acid prescriptions shown $5.6M gross reimbursement (before rebates) ≈ $100 per prescription (gross)

Summed across the 10 of 42 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 485023

mycophenolic acid 180 MG Delayed Release Oral Tablet

38,171 Medicaid prescriptions (Q1–Q4 2025) 41% of Mycophenolic Acid prescriptions shown $3M gross reimbursement (before rebates) ≈ $78 per prescription (gross)

Summed across the 11 of 36 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 485020

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Mycophenolic Acid, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 21 of 78 listed Mycophenolic Acid NDCs with Medicaid activity.

🔍 Compare Mycophenolic Acid products

A representative set of FDA-listed product records for Mycophenolic Acid — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 121 of 121 products — FDA National Drug Code Directory. See every product, package size and price: browse all 121 Mycophenolic Acid NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Mycophenolic Acid RxCUI 7145 1 dose form · 2 strengths
  1. Dose form (SCDF) Delayed Release Oral Tablet RxCUI 485019 In current FDA listings
    Clinical drug / strength (SCD) 180 MG RxCUI 485020 360 MG RxCUI 485023

Look up RxCUI 7145 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Myfortic

🏭 Manufacturers & labelers

Major Pharmaceuticals 10 Biocon Pharma Inc. 10 PD-Rx Pharmaceuticals, Inc. 8 Novartis Pharmaceuticals Corporation 8 American Health Packaging 8 Apotex Corp 8 Ascend Laboratories, LLC 8 Accord Healthcare Inc. 6 Slate Run Pharmaceuticals, LLC 6 Golden State Medical Supply, Inc. 6 Concord Biotech Limited 6 TWi Pharmaceuticals, Inc. 4 Remedyrepack Inc. 4 Advagen Pharma Limited 4 Amta Labs Limited 2 Upsher-Smith Laboratories, LLC 2 Novugen Pharma (USA) LLC. 2 airis PHARMA Private Limited 2 Novartis Pharma Produktions GmbH 2 Mylan Pharmaceuticals Inc. 2 Lupin Pharmaceuticals, Inc. 2 Aurobindo Pharma Limited 2 Bora Pharmaceutical Laboratories Inc. 2 Biocon Limited 1

…and 6 more on the FDA NDC directory.

RxNorm drug class

Mycophenolic Acid belongs to the Antimetabolite Immunosuppressant class.

Pharmacologic class Antimetabolite Immunosuppressant
Drug family (ATC) Selective immunosuppressants

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jul 29, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Mycophenolic Acid.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Mycophenolic Acid after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
21
NDC products indexed
121
Distinct labelers/manufacturers represented
30
Linked representative label ⓘ
Novartis Pharmaceuticals Corporation
Linked label effective
Jul 29, 2026
Composite sections available
23
Linked SPL Set ID
eed26501-890d-4ff6-88e7-6dbea4726e53
Linked SPL Document ID
dd888996-35e0-4e02-af87-7557820412bc
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 21 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Novartis Pharmaceuticals Corporation is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.